| Literature DB >> 28215825 |
Andriana G Kotini1, Chan-Jung Chang1, Arthur Chow2, Han Yuan3, Tzu-Chieh Ho2, Tiansu Wang1, Shailee Vora1, Alexander Solovyov4, Chrystel Husser1, Malgorzata Olszewska1, Julie Teruya-Feldstein5, Deepak Perumal6, Virginia M Klimek7, Alexandros Spyridonidis8, Raajit K Rampal7, Lewis Silverman9, E Premkumar Reddy9, Elli Papaemmanuil10, Samir Parekh6, Benjamin D Greenbaum4, Christina S Leslie3, Michael G Kharas11, Eirini P Papapetrou12.
Abstract
Myeloid malignancy is increasingly viewed as a disease spectrum, comprising hematopoietic disorders that extend across a phenotypic continuum ranging from clonal hematopoiesis to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this study, we derived a collection of induced pluripotent stem cell (iPSC) lines capturing a range of disease stages encompassing preleukemia, low-risk MDS, high-risk MDS, and secondary AML. Upon their differentiation, we found hematopoietic phenotypes of graded severity and/or stage specificity that together delineate a phenotypic roadmap of disease progression culminating in serially transplantable leukemia. We also show that disease stage transitions, both reversal and progression, can be modeled in this system using genetic correction or introduction of mutations via CRISPR/Cas9 and that this iPSC-based approach can be used to uncover disease-stage-specific responses to drugs. Our study therefore provides insight into the cellular events demarcating the initiation and progression of myeloid transformation and a new platform for testing genetic and pharmacological interventions.Entities:
Keywords: acute myeloid leukemia; cancer progression; hPSC-derived hematopoiesis; iPSC disease modeling; induced pluripotent stem cells; leukemia; leukemia progression; myelodysplastic syndrome; myeloid malignancy; transplantation
Mesh:
Substances:
Year: 2017 PMID: 28215825 PMCID: PMC5337161 DOI: 10.1016/j.stem.2017.01.009
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633